For example, while we are currently conducting a randomized placebo-controlled trial to determine whether the sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin can preserve beta-cell function and maintain glucose tolerance in women with recent GDM (ClinicalTrials.Gov NCT03215069), it is of interest that, in men and women with established T2DM and CVD, this medication can also reduce risks of atherosclerotic vascular disease and heart failure [22] (both of which are known to be elevated in women with a history of GDM [3, 9, 10]). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.